Subject Index

A
ACAC microcapsule artificial kidney 568-73
activated carbon 290-1
adolescents
haemodialysis for, 335-41
programme for dialysis, 337
air-bubble trap
automatically controlled, 656-7
aldosterone
plasma, in patients with end-stage kidney disease, 147-52
regulation of in anephric man, 74-81
aluminium hydroxide in RDT 126-39
amino acids
essential and non-essential, 426-8
essential, permeation of, through dialysis membranes, 402-7
peritoneal dialysis and, 393-400
anephric man
insulin catabolism before and after RDT, 119-24
regulation of aldosterone in, 74-81
antibodies and graft rejection
relationship between, 457-9
antibody production in patients on RDT to organisms present in dialysate, 575-6
anticoagulants and thrombus formation 451-2
antigen
sources of for production of ALS, 364-5
antihuman ALS 365
anti-lymphocyte serum (ALS) 364, 388
antisera
production of immunosuppressive, 364-9
antithymocyte globulin (ATG)
clinical experience with, 366-8
species used in production, 368
arterial line monitor and bubble trap
combined, 565-7
arteriovenous fistulae
212-16
complications of, 588-90
construction of, 173-7
monitoring overnight dialysis, 215-16
needle insertion, technique of, 214-15
operating technique, 213-14
postoperative care of patient, 214
preoperative assessment of patient, 213
subcutaneous, for haemodialysis, 173-7
surgery for, 212-14
arteriovenous shunts
190
haemodynamic effects of, and clinical significance of, 642-8
artery-to-artery bypass 177

artificial kidney
capillary film, clinical evaluation of, 632-3
microcapsule, 568-73
aseptic necrosis
in children after transplant, 207
Australia antigen
carriage of by cockroaches, 251-3
carriage of, influence of environment and genetic factors on, 243-6
hepatitis in renal units and, 235-41
in dialysis units, 247-50
axillary artery
to brachial vein bypass, 177

B
blood
linear velocity of, in thrombus formation, 447-8
blood factor depositions
effect of on dialysance of middle weight molecules in re-used dialysers, 278-85
blood loss
characteristics of various, 443
blood perfusion
activated carbon and, 290-300
blood pressure
in 'adequate' dialysis, 267-8
blood samples
as cause of anaemia, 439
bloodstream for haemodialysis
access to, 212-16
blood transfusions
and sensitisation, relationship between, 460-1
effect of, and hepatitis, 28-9
in 'adequate' dialysis, 269
blood trapping
within dialysers, causes of, 443-6
blood urea
nitrogen assessment in dialysis, 265
bone age
in children on RDT, 181
bone remodelling
effect of phosphate binding agents on, 126-39
brachial artery fistula 177
bubble-flow meter
accuracy of, 694-7
bubble trap
and arterial line monitor, combined, 565-7
level of blood in, 39

calcification
effect of aluminium hydroxide on metastatic, 135-6
calcium and phosphorus
assessment in dialysis, 267
California personality test
360–1

capillary film artificial kidney
clinical evaluation of, 632–3

carbon
activated, and blood perfusion, 290–300

children
dialysis in, 181–6, 187–90, 191–9, 325–33
home dialysis, 335–41
renal transplantation in, 200–209, 328

clearance efficiency
of Cordis Dow artificial kidney, instantaneous determination of, 558–62

coated activated carbon
294

computer
analysis of data on children on RDT and transplants, 191–9

cuprophane membranes
comparative performance characteristics of different thicknesses, 594–5

cuprophane PT
150, 402, 403, 404, 406

D

DASCO SP 400 disposable dialyser
592–3

de-aeration
cause, consequences, and cure of, 605–10

diabetic complications
of renal transplantations, 352–3

diabetic patients
morbidity and mortality in renal transplants, 345–57

dialysate
antibody production to organisms in, 575–6
high sodium, benefit of during maintenance therapy, 111–16

dialyser blood loss
449
measurement of, 440–2

dialyser rupture
as source of blood loss, 439

dialysers
AB-Gambo, re-use of, 283
and blood loss in RDT, 437–53
Baxter Travenol RSP coil pool, 596
blood loss characteristics, 443
coll, 44, 68
Dasco SP 400 disposable, 592–3
factors responsible for blood trapping within, 443–6
Gambo Lundia multilayer, 601–4
Kii, 35, 37, 67
Mini-D for paediatric dialysis, 628–31
Nephranon coil, 596–9
parallel flow, adapting to the Travenol act
re-used, effect of blood factor depositions on dialysate of middle weight molecules, 278–85
re-used, sterilisation procedures, 278–9
Rhône-Poulenc-B, re-use of, 283
Ultra 100 coil, 596–9
Ultraflo cartridge, 596–9

dialysis bath
closed circuit, 55–64

dialysis units
epidemiology of hepatitis in, 247–50
diet and amino acids in uraemia, 419–34

E

epiphyseal osteonecrosis
after transplantation, 376–84
predisposing factors, 380–1
surgical treatment, 379–80, 382, 383

erythrocyte mass transfer rates
effects of on solute clearance measurements during haemodialysis, 303–13, 315–19

F

femoral heads
slippage of in children after transplantations, 207–8

femoral neck
atrophy of, in children after transplantations, 207

fistula needles
increased flow rates through perforated, 654–5

fractures
stress in children after transplantations, 207

G

glomerulonephritis
as cause of terminal uraemia, 5

glucose
utilisation in RDT, 143

gonadotrophin
secretion in uraemia, 555–7

graft failure
by rejection and tissue typing, 17–20
relationship with blood transfusion, and with pregnancy, 14–17

growth hormone
influence of dialyser on, 97

growth in children
after transplantations, 208
on dialysis, 181

H

HAA-antibodies
in the study of hepatitis, 84

haemagglutinen test
for HAA-antibodies, 85–6

haemocrit
in adequate’ dialysis, 268

haemodialysers
see also dialysers
automatic peritoneal, 563–4
blood level in bubble trap, 39

haemodialysis
accuracy of bubble flow method for determining blood-flow rate, 634–7
adequacy of, 665–70
assessment of patients with reduced small molecules removal, 67–72
automatically controlled air-bubble trap, 656–7
chronic intermittent, effects of zinc-containing dialysis membranes on zinc metabolism, 548–59
effects of erythrocyte mass transfer rates on solute clearance measurements, 303–313, 315–19
high sodium dialysate, benefits of, 111–46
high sodium during maintenance therapy, 111–16
in children, 325–33 (see also ‘Children’)
effectiveness of, in removing peptides inhibiting glucose utilisation, 142–5
intermittent, end-to-side anastomosis between great saphenous vein and subcutaneously fixed femoral artery, 638–41
problems of vascular access for, 173–7
selection of patients for chronic, 107–71
simultaneous disequilibrium studies on urea and creatinine, 623–7
sources of blood loss during, 438–40
**haemodynamic**
effects of A-V shunts, 642–8

**haemolysis**
in RDT patients, 91–4
heparin
35S removal in anephric patients undergoing RDT, 614–17
hepatic dysfunction
in children after transplantation, 205
hepatitis
and RDT, and transplantation, 27–8
anti-HAA immunity in renal units, 84–7
at Guy’s Hospital, 228–34
Australia antigen, in renal units, 235–41
carriage of AA by cockroaches, 251–3
cardiovascular effects, 297–308
control of in a renal unit, 618–22
epidemiology of in dialysis units, 247–50
prevention programme for dialysis units, 250
histocompatibility
influence of on graft and patient survival in primary cadaver kidney transplantation, 466–73

**HL-A antisera**
production of by planned immunisations, 475–82

**home dialysis**
6–8
anxiety about equipment, 39
A-V fistula in, 212
children and adolescents, 333–41
difficulties of patients, 35–41
hidden costs to patients, 36–9
problems of patients, 35–43
single needle method, 690–1
social life and, 39
hypertension
after transplantation, 354–5
control of by haemodialysis, 154
in children after transplantation, 205–6

**immunisation**
production of HL-A antisera by planned, 475–82

**immunisation schedule**
365

**immunosuppressive antisera**
production of, 364–9

**insulin**
catabolism in chronic uraemia, 119–24
influence of dialyser on, 97

**intoxications**
exogenous, haemodialysis for, 326
intracellular-free amino acids
in muscle tissue, effect of peritoneal dialysis on, 393–400

K

**kidney preservation**
in hypothermic ‘cytoplasmic’ solution, 491–8

**kidney transplants**
effect of cooled blood-free solutions on function of, 500–4

L

**life**
quality of, in ‘adequate’ dialysis, 269

**lung water**
elevation in uraemic patients, 542–6

**lymphotoxicity**
variation in patients and transplant donors, 461

M

**mass transfer rates**
through membranes, 402–6
**medical complications**
in children after transplantation, 205
membranes
26
causes of thrombus formation on dialysis, 446–52
cuprophane, comparative performance characteristics of different thicknesses, 594–5
effects of zinc-containing on zinc metabolism, 548–50
high permeability of, 55–64
nature of, and thrombus formation, 448–51
permeation of essential amino acids through dialysis, 402–7
membrane surfaces
configuration and thrombus formation, 451
metabolism
red-cell, and haemolysis in RDT patients, 91–4
microcapsule artificial kidney
568–73
middle molecule hypothesis
67
**Mini-D dialyser**
for paediatric dialysis, 628–31
**molecules**
clearance of middle size, 658–60
medium molecular weight, clearance by microcapsule artificial kidney, 569–71
in serum, 409
middle weight, effect of blood factor deposition on in re-used dialysers, 278–85
reduced small, removal of, 67–72
monitoring
of immunosuppressive effect of sera, 315–316
overnight, fistula dialysis, 215–16
monkey tests
of immunosuppressive ALG, 366
muscle biopsy
on uraemic patients, 393–4
necrosis
aseptic, in children after transplantation, 207
neflex DVF 30B
402, 403, 404, 406
nephrectomy
total, 20–1
nephrectomy-splenectomy
mortality of diabetic patients, 348
nephrophane
402, 403, 404, 405, 406
neuropathy
prevention of peripheral in ‘adequate’ dialysis, 268
non-coated activated carbon
291–4
orthopaedic complications
in children after transplantations, 207–8
paediatric dialysis
Mini-D dialyser for, 628–31
patients
haemodialysis, assessment of, with reduced small molecules removal, 67–72
home dialysis and, 35–43
nephrectomised and aldosterone regulation, 74–81
screening for HAA in, 86–7
selection of, for chronic haemodialysis, 167–71
sexual problems of, on RDT, 271–3
uraemic, extravascular lung water in resting and exercising, 542–6
uraemic, parenteral administration of a new cephalosporin, 577–9
peptides
inhibiting glucose utilisation, ineffectiveness of, 142–5
perfusion
activated carbon and blood, 290–300
results of continuous hypothermic albumin, 484–9
perfusion dynamics
and function of kidney transplants, effect of cooled blood-free solutions on, 500–4
peritoneal dialysis
automatic dialyser, 569–4
effect on intracellular free amino acids, 393–400
personality tests
360–2
PHO III Gamma camera
investigations with, 536–40
phosphate binding agents
effect of on bone remodelling, 126–39
Pier-Harris Self Esteem personality test
361
plasma renin
activity in RDT, 154–9
platelet adhesiveness
and thrombus formation, 446–7
pregnancy
following transplantation, 15, 16–17
puberty
in children on dialysis, 181
red-cell metabolism
and haemolysis in RDT patients, 91–4
regular dialysis treatment
age at start of, and duration, 6–8
aluminium hydroxide and, 126–39
and reduced small molecule removal, 67–72
A-V fistula in, 212
children, 181–6, 187–90, 191–9 (see also Children)
daily dialysis programme, 44–8
daily programme approach, 44–50
death, causes of, 22–4
diabetic patients, 346–7
dialysers and blood loss, 437–53
effect of phosphate binding agents on bone remodelling, 126–39
extravascular lung water in patients on, 542–6
factors influencing rehabilitation, 257–63
heparin 32S removal in anephric patients, 614–17
in home, 6–7, 35–41 (see also Home dialysis)
in hospital, 7–8
insulin catabolism in chronic anaemia before and after, 119–24
middle molecules hypothesis, 67–72
plasma aldosterone levels in renal failure, 147–52
plasma renin activity, 154–9
pregnancy and, 15, 16–17
red-cell metabolism and haemolysis, 91–4
rehabilitation following, 24–5 (see also Rehabilitation)
regulation of aldosterone in anephric man, 74–81
rosette inhibition tests, 507–11
screening for HAA in transplant patients, 86–7
sexual problems of patients, 271–3
survival rates after transplantation, 9–14
rehabilitation
age and professional status, 260
change of occupation and retraining, 259
diabetic patients, 355–7
duration of therapy and professional status, 261–2
long-term follow-up of patients and families, 359–63
mortality and morbidity in diabetic patients, 345–57
operative and urological complications, 353–4
preservation of transplants, 484
rehabilitation of patients following, 25–6, 371–5
renal function and hypertension after, 354–5
renography of, 533–6
roselle inhibition tests, 507–11
scintigraphy of by Gamma camera, 536–40
screening patients for HAA, 86–7
sexual problems of patients, 273–5
survival rates on RDT after, 9–14
renal units
anti-HAA immunity in, 84–7
control of hepatitis in, 618–22
renin-angiotensin system
anephric subjects and, 78
renography
radioisotope of renal transplants, 533–6
roselle inhibition tests
for evaluating serum immunosuppression activity, 507–11
saphenous vein grafts
in establishing A-V fistulae, 173, 175
scintigraphy of renal transplants, 536–40
Scribner shunt
177, 212, 332
serum albumin
assessment in dialysis, 266–7
serum creatinine
assessment in dialysis, 266
serum half-life
study of in relation to renal function, 577–9
serum potassium
assessment in dialysis, 266
sexual potency in 'adequate' dialysis, 269–70
sexual problems of patients on RDT and after renal transplantation, 271–5
shunt
and fistula connection as source of blood loss, 439
silastic cannula, 176
solute clearance measurements
during haemodialysis, effects of erythrocyte mass transfer rates, 303–13, 315–19
sterilisation procedures
for re-used dialysers, 278–9
steroid toxicity
in children after transplantation, 206
stress fractures
in children after transplantation, 207
thrombus formation
on dialysis membranes, causes of, 446–52
tissue weight gain
in dialysis, 267

transfusion
rate of in dialysis, 331

transport-ATPase
by uraemic toxins, inhibition of, 521–8

transport model
for efflux of solute from erythrocytes in blood, 304–5

ultrafiltration-filtration system
for treatment of uraemia, 584–7

ultrasonic scanning
for renal biopsy in renal failure, 611–13

uraemia
(see also Renal failure, acute; Renal failure, chronic)
treatment of by an ultrafiltration-filtration system, 584–7
ultrasonic scanning for renal biopsy in, 611–13

uraemic symptoms
analysis of characteristics of metabolites responsible for, 573

uraemic toxins
inhibition of transport-ATPase by, 521–8

uraemic waste recovery
514–20

urological complications
in children after transplantation, 204
of renal transplants in diabetics, 355–4

vascular complications
in children after transplantations, 204–5

vein-to-vein bypass
177

vein-to-vein shunts
190

viral hepatitis
in renal units, 84

Visking-cellophane
402, 403, 404, 406